From SEDAR:
2319634.2
Form 51–102F3
Material Change Report
Item 1 Name and Address of Company
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Glenlyon Business Park
Burnaby, B.C.
V5J 5J8
(“Tekmira”)
Item 2 Date of Material Change
May 30, 2008
Item 3 News Release
A press release was issued by Tekmira through Marketwire on June 2, 2008.
Item 4 Summary of Material Change
Tekmira Pharmaceuticals Corporation (“Tekmira”) announced on June 2, 2008 that it had completed the business combination (the “Business Combination”) with Protiva Biotherapeutics
Inc. (“Protiva”).
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM